A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation – HAILO

Study Location:

Baltimore

Topic:

HIV

Clinicaltrials.gov Link:

N/A

IRB#:

NA_00086904

Coordinator:

Abby Dowling, RN

Enrollment:

Closed

Trial Period:

Ongoing

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an established longitudinal study of HIV-infected participants. At the time of enrollment in A5322, these participants were enrolled and followed in the Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) study (A5001) (or had recently completed follow-up in ALLRT [A5001]), which had enrolled participants who received their first immune-based or antiretroviral therapies (ART) or treatment strategies through randomized ACTG clinical trials.  

Participants actively followed in the ALLRT (A5001) at the time of enrollment into A5322 or completed follow-up in ALLRT (A5001) who were ART-naïve at the time of enrollment into their ALLRT (A5001) parent protocol, and who were 40 years of age or older at their time of enrollment into A5322.

410-955-2898

Categories

Location
Topic

Clinical Trials

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More